Tempest's charter amendment vote fails to pass at Sept 15 meeting; reconvenes Oct 14

Tempest Therapeutics, Inc.

Special meeting reconvened Sept 15, 2026; quorum of 10,760,144 shares (72.7% outstanding) present.
Proposal to replace supermajority voting and allow written consent requires 75% affirmative vote; not achieved.
Meeting adjourned to Oct 14, 2026 at 12:00 pm ET via webcast; record date remains May 28, 2026.
Proxies already submitted will be voted unless revoked; no changes to proposal.
Company engaged Sodali & Co. to assist with proxy solicitation for the vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.